Get the Stockscreener App
5.78
0.69%
-0.04
Brainsway Ltd ADR stock is currently priced at $5.78, with a 24-hour trading volume of 19,564.
It has seen a -0.69% decreased in the last 24 hours and a +2.85% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.72 pivot point. If it approaches the $5.92 resistance level, significant changes may occur.
Previous Close:
$5.82
Open:
$5.89
24h Volume:
19,564
Market Cap:
$96.16M
Revenue:
$28.79M
Net Income/Loss:
$-8.19M
P/E Ratio:
-7.4103
EPS:
-0.78
Net Cash Flow:
$-5.38M
1W Performance:
+21.43%
1M Performance:
+2.85%
6M Performance:
+40.29%
1Y Performance:
+290.54%
1D Range:
$5.69
$5.90
52W Range:
$1.38
$7.615
Brainsway Ltd ADR Stock (BWAY) Company Profile
Name
Brainsway Ltd ADR
Sector
Industry
Phone
972 2 582 4030
Address
Bynet Building, 3rd Floor 19 Hartum Street Har Hotzvim, Jerusalem
Brainsway Ltd ADR Stock (BWAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-22 | Initiated | Loop Capital | Buy |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | Northland Capital | Outperform |
| May-13-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-13-19 | Initiated | Ladenburg Thalmann | Buy |
| May-13-19 | Initiated | Oppenheimer | Outperform |
| May-13-19 | Initiated | Raymond James | Outperform |
View All
Brainsway Ltd ADR Stock (BWAY) Latest News
BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease
GlobeNewswire Inc.
After Plunging -13.63% in 4 Weeks, Here's Why the Trend Might Reverse for Brainsway (BWAY)
Zacks Investment Research
All You Need to Know About Brainsway Ltd. Sponsored ADR (BWAY) Rating Upgrade to Buy
Zacks Investment Research
BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems
GlobeNewswire Inc.
Best Momentum Stocks to Buy for March 11th
Zacks Investment Research
New Strong Buy Stocks for March 11th
Zacks Investment Research
Brainsway Ltd ADR Stock (BWAY) Financials Data
Brainsway Ltd ADR (BWAY) Revenue 2024
BWAY reported a revenue (TTM) of $28.79 million for the quarter ending September 30, 2023, a -2.79% decline year-over-year.
Brainsway Ltd ADR (BWAY) Net Income 2024
BWAY net income (TTM) was -$8.19 million for the quarter ending September 30, 2023, a +24.36% increase year-over-year.
Brainsway Ltd ADR (BWAY) Cash Flow 2024
BWAY recorded a free cash flow (TTM) of -$5.38 million for the quarter ending September 30, 2023, a -5.04% decrease year-over-year.
Brainsway Ltd ADR (BWAY) Earnings per Share 2024
BWAY earnings per share (TTM) was -$0.50 for the quarter ending September 30, 2023, a +19.35% growth year-over-year.
About Brainsway Ltd ADR
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
0.77%
Cap:
|
Volume (24h):